Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Omicron may not evade all monoclonal antibodies, lab study suggests - Health News

The coronavirus will likely evade Paxlovid eventually. What that will mean for the pandemic is unclear

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6

The Omicron Variant Partly Dodged Vaccines In A Blood Study

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Frontiers Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic - ScienceDirect

Dominant Omicron Subvariants Better at Evading Vaccines, Antibody Treatments

Newest Omicron subvariants can evade boosters, antibody therapies